Brainstorm Cell Therapeutics (NASDAQ:BCLI) Rating Lowered to “Sell” at StockNews.com

Brainstorm Cell Therapeutics (NASDAQ:BCLI) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a report issued on Tuesday.

Brainstorm Cell Therapeutics Trading Down 0.8 %

NASDAQ:BCLI opened at $1.17 on Tuesday. The firm has a 50 day moving average of $2.65 and a 200-day moving average of $4.78. Brainstorm Cell Therapeutics has a 1 year low of $1.09 and a 1 year high of $11.89. The stock has a market capitalization of $6.22 million, a P/E ratio of -0.34 and a beta of 0.40.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.60) earnings per share for the quarter, hitting the consensus estimate of ($0.60). During the same quarter in the prior year, the firm posted ($4.05) earnings per share. As a group, analysts forecast that Brainstorm Cell Therapeutics will post -2.85 EPS for the current fiscal year.

Institutional Investors Weigh In On Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Armistice Capital LLC purchased a new position in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned 11.30% of Brainstorm Cell Therapeutics at the end of the most recent reporting period. 14.33% of the stock is currently owned by institutional investors.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.